AMGEN ANNOUNCES POSITIVE NEW DATA AT EADV 2022 FOR OTEZLA® (APREMILAST)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Mizuho Securities Reiterates Neutral Rating on Amgen (AMGN), PT $208, 'Lukewarm Lumakras ESMO Data'
September 12, 2022 9:44 AM EDTMizuho Securities analyst Salim Syed reiterated a Neutral rating and $208.00 price target on Amgen (NASDAQ: AMGN).
The analyst comments "And last night, we received the first part of detailed data from Amgen's Ph3 CB200 trial (Lumakras in 2L+ NSCLC). While we expect to receive the second part of detailed data later today, the first part showed (a) a decrease in ORR from 36% in CB100 to yesterday's 28%, (b) Gr3 liver enzyme elevations in about 10% of patients -- known... More
